William Mr. Burke Sells 5,347 Shares of AxoGen (NASDAQ:AXGN) Stock

AxoGen, Inc. (NASDAQ:AXGN) Director William Mr. Burke sold 5,347 shares of AxoGen stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $24.01, for a total transaction of $128,381.47. Following the completion of the transaction, the director owned 100 shares of the company’s stock, valued at $2,401. This represents a 98.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

AxoGen Stock Performance

Shares of NASDAQ:AXGN traded down $0.42 during trading on Friday, hitting $23.57. 989,751 shares of the company were exchanged, compared to its average volume of 846,646. AxoGen, Inc. has a 52-week low of $9.22 and a 52-week high of $24.25. The stock has a 50 day moving average of $17.74 and a 200 day moving average of $14.44. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.14 and a quick ratio of 2.67. The company has a market cap of $1.09 billion, a PE ratio of -471.40 and a beta of 1.09.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03. AxoGen had a negative return on equity of 1.96% and a negative net margin of 0.98%.The company had revenue of $60.08 million for the quarter, compared to analyst estimates of $56.90 million. AxoGen has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that AxoGen, Inc. will post -0.29 EPS for the current year.

Analyst Ratings Changes

Several analysts have weighed in on AXGN shares. Wall Street Zen raised AxoGen from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Jefferies Financial Group reissued a “buy” rating on shares of AxoGen in a research note on Wednesday, October 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AxoGen in a research note on Wednesday, October 8th. Canaccord Genuity Group increased their price objective on AxoGen from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Finally, JMP Securities set a $34.00 price objective on AxoGen in a report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $28.86.

Institutional Trading of AxoGen

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Future Financial Wealth Managment LLC bought a new position in AxoGen in the 3rd quarter worth $27,000. State of Alaska Department of Revenue bought a new stake in shares of AxoGen during the 3rd quarter valued at about $43,000. AdvisorNet Financial Inc increased its position in shares of AxoGen by 500.0% during the third quarter. AdvisorNet Financial Inc now owns 4,800 shares of the medical equipment provider’s stock valued at $86,000 after buying an additional 4,000 shares during the period. Tower Research Capital LLC TRC raised its stake in AxoGen by 189.9% in the second quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider’s stock worth $55,000 after buying an additional 3,327 shares in the last quarter. Finally, AlphaQuest LLC lifted its holdings in AxoGen by 882.2% in the second quarter. AlphaQuest LLC now owns 6,276 shares of the medical equipment provider’s stock worth $68,000 after buying an additional 5,637 shares during the period. Hedge funds and other institutional investors own 80.29% of the company’s stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.